Sorry, you need to enable JavaScript to visit this website.

You are here

Inflammation & Remodeling


The Inflammation & Remodeling Research Unit. led by Christinner Perros-Huguet, CSO, is focused on discovering and developing novel and differentiated therapeutic options targeting chronic inflammatory diseases. Chronic inflammation can result from sensing and integrating injury or danger signals including infectious agents, free radicals and oxidative stress. The unit focuses on three mechanistic themes each defining a distinct intervention point in the cycle of disease chronicity. The three mechanistic areas include: 1) epithelial, endothelial and parenchymal sensors of danger signals and the engagement of the innate immune system; 2) integrators and amplifiers of inflammation including cell signaling, chemotaxis, production of inflammatory mediators by various cell types and disruption of the mucosal / microbiome barrier surface; and 3) targeting tissue remodeling and fibrosis by regulating TGFB signaling, matrix stiffness, and fibroblast proliferation.

WRD is interested in establishing alliances to develop therapeutics, expand disease biology understanding, and identify biomarkers that impact:

  • Diabetic nephropathy
  • IgA nephropathy, Lupus nephritis and membranous nephropathy
  • Autosomal dominant polycystic kidney disease
  • Acute kidney injury (prevention and treatment)
  • COPD
  • Severe asthma
  • Pulmonary hypertention and idiopathic Pulmonary Fibrosis
  • Other pulmonary, liver and skin fibrotic diseases

Specific areas of interest include:

  • Innate immune suppressors
  • Oxidative stress modulators
  • Anti-fibrotics
  • Technology platforms and products to help understand patient segmentation in the disease areas of interest

Not actively seeking partnering opportunities in:

  • Corticosteroids
  • ACE / ARB


R & D Brochure


Understand what R&D is looking for in an early stage opportunity.


Connect With Us


Reach out. We want to hear from you.